Original ArticlesA Double-blind, Randomized, Crossover Study of Prosigne Versus Botox in Patients With Blepharospasm and Hemifacial SpasmRieder, Carlos R.M. MD, PhD*†; Schestatsky, Pedro MD*†; Socal, Mariana Peixoto MD*; Monte, Thaís Lampert MD*; Fricke, Daniele MD*; Costa, João MD‡; Picon, Paulo Dornelles MD, PhD*†Author Information *Department of Neurology, Hospital de Clínicas de Porto Alegre, Brazil; †Brazilian Ministry of Health, Brasilia, Brazil; and ‡Department of Neurology, Santa Maria University Hospital, Lisbon Faculty of Medicine, Institute of Molecular Medicine, Lisbon, Portugal. Address correspondence and reprint requests to Pedro Schestatsky, MD, Movement Disorders Unit, Department of Neurology, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, RS, Brazil. E-mail: email@example.com. Clinical Neuropharmacology: January-February 2007 - Volume 30 - Issue 1 - p 39-42 doi: 10.1097/01.WNF.0000236771.77021.3C Buy Metrics Abstract There is a lack of evidence on the clinical efficacy and safety of the recently released Chinese botulinum toxin serotype A (Prosigne) for the treatment of focal dystonias and hemifacial spasm. Determining a more precise role of Prosigne in the treatment of such conditions is of paramount importance, because botulinum toxin type A treatments have a huge economic implication in health services, especially in developing countries. The aim of our study was to compare the efficacy and safety of Prosigne in the treatment of blepharospasm and hemifacial spasm in comparison to Botox. We performed a double-blind, randomized, crossover study enrolling 26 patients. There were no significant differences between Prosigne and Botox regarding subjective global improvement, response onset, efficacy duration, and incidence and severity of adverse events. Our results suggest that Prosigne and Botox are comparable with respect to efficacy and safety for the short-term treatment of blepharospasm and hemifacial spasm. © 2007 Lippincott Williams & Wilkins, Inc.